PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16081343-1 2005 Our recent study indicated that MTHFR C677T polymorphism may involve in genetic control of blood pressure response to treatment by benazepril, an ACE inhibitor. benazepril 131-141 angiotensin I converting enzyme Homo sapiens 146-149 12860503-3 2003 OBJECTIVE: This study measured the impact of substituting low-dose, fixed-combination therapy using the calcium channel blocker (CCB) amlodipine and the angiotensin-converting enzyme (ACE) inhibitor benazepril for high-dose CCB monotherapy or dual therapy with a CCB and an ACE inhibitor on antihypertensive drug costs, the incidence of adverse events, and blood-pressure control. benazepril 199-209 angiotensin I converting enzyme Homo sapiens 153-182 15793787-5 2005 A comparison of the reducing urinary protein efficacy of benazepril was made between the patients with different ACE genotypes. benazepril 57-67 angiotensin I converting enzyme Homo sapiens 113-116 15793787-9 2005 CONCLUSION: Benazepril could decline the rate of urinary protein excretion in patients with primary chronic glomerulonephritis, and significant relationship was observed between ACE gene polymorphism and the reducing urinary protein efficacy of ACEI. benazepril 12-22 angiotensin I converting enzyme Homo sapiens 178-181 15773232-0 2005 Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. benazepril 63-73 angiotensin I converting enzyme Homo sapiens 122-125 14576031-1 2003 After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. benazepril 68-76 angiotensin I converting enzyme Homo sapiens 81-84 15226090-5 2004 The purpose of this study was to investigate whether short-term blood pressure control by benazepril, an ACE inhibitor, was modulated by C677T MTHFR gene polymorphism. benazepril 90-100 angiotensin I converting enzyme Homo sapiens 105-108 12860503-3 2003 OBJECTIVE: This study measured the impact of substituting low-dose, fixed-combination therapy using the calcium channel blocker (CCB) amlodipine and the angiotensin-converting enzyme (ACE) inhibitor benazepril for high-dose CCB monotherapy or dual therapy with a CCB and an ACE inhibitor on antihypertensive drug costs, the incidence of adverse events, and blood-pressure control. benazepril 199-209 angiotensin I converting enzyme Homo sapiens 184-187 12484510-4 2002 To resolve this dilemma, we compared changes in renal function and left ventricular function and the safety and effectiveness of benazepril, an ACE inhibitor, in patients with diabetic nephropathy, with or without LVH. benazepril 129-139 angiotensin I converting enzyme Homo sapiens 144-147 12913981-0 2003 [The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction]. benazepril 52-62 angiotensin I converting enzyme Homo sapiens 12-41 18370561-0 1998 Protection of Renal Function with ACE Inhibitors: Experience with Benazepril. benazepril 66-76 angiotensin I converting enzyme Homo sapiens 34-37 11896508-4 2002 The current study tests the hypothesis that a fixed-dose combination of an ACE inhibitor, benazepril (B) with the dihydropyridine CCB, amlodipine (A), will further reduce arterial pressure and reduce atherogenic lipid fractions compared to either agent alone. benazepril 90-100 angiotensin I converting enzyme Homo sapiens 75-78 11817991-14 2002 Thus, the quality-adjusted survival benefits and overall cost savings seen in benazepril recipients over a prolonged period (2 to 7 years) indicate that the strategy of prescribing benazepril to reduce progression of renal disease in patients with renal insufficiency is both clinically and economically beneficial compared with current antihypertensive regimens without ACE inhibition. benazepril 78-88 angiotensin I converting enzyme Homo sapiens 371-374 11677377-1 2001 OBJECTIVE: The aim of this open multicentric study was to investigate the efficacy and safety of the addition of an angiotensin converting enzyme (ACE) inhibitor (benazepril, 10 mg/day) or a diuretic (hydrochlorothiazide, 12.5 mg/day) for 4 weeks in patients with mild to moderate essential hypertension having been treated for 4 weeks by an angiotensin II antagonist (valsartan, 80 mg/day) but still having a diastolic blood pressure (BP) > 90 mmHg on this medication given alone. benazepril 163-173 angiotensin I converting enzyme Homo sapiens 116-145 11677377-1 2001 OBJECTIVE: The aim of this open multicentric study was to investigate the efficacy and safety of the addition of an angiotensin converting enzyme (ACE) inhibitor (benazepril, 10 mg/day) or a diuretic (hydrochlorothiazide, 12.5 mg/day) for 4 weeks in patients with mild to moderate essential hypertension having been treated for 4 weeks by an angiotensin II antagonist (valsartan, 80 mg/day) but still having a diastolic blood pressure (BP) > 90 mmHg on this medication given alone. benazepril 163-173 angiotensin I converting enzyme Homo sapiens 147-150 11090788-0 2000 Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. benazepril 107-117 angiotensin I converting enzyme Homo sapiens 66-95 12069356-7 2002 Patients were primarily treated with a combination of amlodipine (5 to 20 mg daily), a calcium antagonist, and benazepril (2.5 to 5 mg daily), an ACE inhibitor in an effort to reduce their blood pressure at the office to < 130/85 mmHg. benazepril 111-121 angiotensin I converting enzyme Homo sapiens 146-149 9929757-2 1999 Although some angiotensin-converting enzyme (ACE) inhibitors have been associated with pancreatitis, to the knowledge of the authors this is the first reported case involving benazepril. benazepril 175-185 angiotensin I converting enzyme Homo sapiens 14-43 9929757-2 1999 Although some angiotensin-converting enzyme (ACE) inhibitors have been associated with pancreatitis, to the knowledge of the authors this is the first reported case involving benazepril. benazepril 175-185 angiotensin I converting enzyme Homo sapiens 45-48 10028949-3 1999 A multicenter European study was designed to determine whether the ACE inhibitor benazepril was safe and effective in protecting residual renal function in patients with various renal diseases and mild to moderate renal failure. benazepril 81-91 angiotensin I converting enzyme Homo sapiens 67-70 11273348-0 1998 An open clinical trial of benazepril--a new ACE inhibitor in mild-moderate hypertension. benazepril 26-36 angiotensin I converting enzyme Homo sapiens 44-47 11273348-1 1998 Benazepril hydrochloride, a new non-sulfhydryl ACE inhibitor (ACEI) was studied in a titrated dose of 10 mg-20 mg once a day for 6 weeks in 42 mild to moderate adult hypertensive patients with sitting diastolic blood pressure (SDBP) 95-114 mm Hg. benazepril 0-24 angiotensin I converting enzyme Homo sapiens 47-50 18370561-5 1998 Benazepril, through its metabolite benazeprilat, is a non-sulfhydryl orally active ACE inhibitor. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 83-86 9004094-2 1996 In AIPRI trial (ACE-inhibition in the progression of renal insufficiency) the ACE-inhibitor benazepril was able to protect patients with mild-to-moderate renal disease against the progression of renal insufficiency. benazepril 92-102 angiotensin I converting enzyme Homo sapiens 16-19 9407424-2 1997 The Angiotensin-converting-enzyme Inhibition on Progressive Renal Insufficiency (AIPRI) Study showed that the ACE inhibitor benazepril provides protection against loss of renal function in patients with chronic renal insufficiency (CRI) caused by various renal diseases. benazepril 124-134 angiotensin I converting enzyme Homo sapiens 4-33 9407424-2 1997 The Angiotensin-converting-enzyme Inhibition on Progressive Renal Insufficiency (AIPRI) Study showed that the ACE inhibitor benazepril provides protection against loss of renal function in patients with chronic renal insufficiency (CRI) caused by various renal diseases. benazepril 124-134 angiotensin I converting enzyme Homo sapiens 110-113 9407424-10 1997 Many patients from both treatment groups (64% on benazepril and 61% on placebo) received ACE inhibitors during follow-up. benazepril 49-59 angiotensin I converting enzyme Homo sapiens 89-92 9407447-2 1997 We tested the hypothesis that preventative treatment with the angiotensin converting enzyme (ACE) inhibitor benazepril in patients with chronic renal insufficiency is cost-effective. benazepril 108-118 angiotensin I converting enzyme Homo sapiens 62-91 9407447-2 1997 We tested the hypothesis that preventative treatment with the angiotensin converting enzyme (ACE) inhibitor benazepril in patients with chronic renal insufficiency is cost-effective. benazepril 108-118 angiotensin I converting enzyme Homo sapiens 93-96 9335410-0 1997 Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. benazepril 22-32 angiotensin I converting enzyme Homo sapiens 111-114 9220694-3 1997 Combined ACE inhibitor/CCB therapy (amlodipine-benazepril) was introduced in 1995. benazepril 47-57 angiotensin I converting enzyme Homo sapiens 9-12 9220694-11 1997 Once a patient has been maintained on a stable dose of a CCB/ACE inhibitor, substitution with amlodipine-benazepril should be considered. benazepril 105-115 angiotensin I converting enzyme Homo sapiens 61-64 9286946-4 1997 In 12 patients measurements were repeated after a 2-month addition of the ACE inhibitor benazepril (10 mg/d P.O. benazepril 88-98 angiotensin I converting enzyme Homo sapiens 74-77 9273485-0 1997 [Experience with benazepril, a long-acting ACE inhibitor, in the management of diabetic hypertension]. benazepril 17-27 angiotensin I converting enzyme Homo sapiens 43-46 9273485-1 1997 The therapeutic advantage of the long acting ACE-inhibitor benazepril in a 12 weeks intervention period on 23 diabetic (3 IDDM, 20 NIDDM) patients with essential hypertension was studied. benazepril 59-69 angiotensin I converting enzyme Homo sapiens 45-48 9004094-2 1996 In AIPRI trial (ACE-inhibition in the progression of renal insufficiency) the ACE-inhibitor benazepril was able to protect patients with mild-to-moderate renal disease against the progression of renal insufficiency. benazepril 92-102 angiotensin I converting enzyme Homo sapiens 78-81 8834707-0 1996 Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. benazepril 96-106 angiotensin I converting enzyme Homo sapiens 50-79 8596594-0 1996 Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. benazepril 54-64 angiotensin I converting enzyme Homo sapiens 14-43 8596594-4 1996 We conducted a study to determine the effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases. benazepril 92-102 angiotensin I converting enzyme Homo sapiens 52-81 9328608-0 1996 Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria. benazepril 28-38 angiotensin I converting enzyme Homo sapiens 10-13 7553405-1 1995 BACKGROUND: Benazepril hydrochloride is a non-sulfhydryl-containing, angiotensin-converting enzyme (ACE) inhibitor. benazepril 12-36 angiotensin I converting enzyme Homo sapiens 69-98 7553405-1 1995 BACKGROUND: Benazepril hydrochloride is a non-sulfhydryl-containing, angiotensin-converting enzyme (ACE) inhibitor. benazepril 12-36 angiotensin I converting enzyme Homo sapiens 100-103 7998853-1 1994 PURPOSE: To assess the effects of benazepril (ACE inhibitor) on arterial blood pressure (ABP) and left ventricular mass index (LVMI). benazepril 34-44 angiotensin I converting enzyme Homo sapiens 46-49 7923309-0 1994 Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. benazepril 92-102 angiotensin I converting enzyme Homo sapiens 52-81 7923309-1 1994 The purpose of this study was to determine whether patients whose blood pressure failed to normalize while receiving monotherapy with atenolol would experience further blood pressure lowering by adding the angiotensin-converting enzyme (ACE) inhibitor benazepril hydrochloride to their treatment regimen. benazepril 252-276 angiotensin I converting enzyme Homo sapiens 206-235 7923309-1 1994 The purpose of this study was to determine whether patients whose blood pressure failed to normalize while receiving monotherapy with atenolol would experience further blood pressure lowering by adding the angiotensin-converting enzyme (ACE) inhibitor benazepril hydrochloride to their treatment regimen. benazepril 252-276 angiotensin I converting enzyme Homo sapiens 237-240 8297690-1 1994 OBJECTIVES: To determine the anti-ischaemic effects of a new angiotensin converting enzyme inhibitor, benazepril, compared with nifedipine, alone and in combination, in chronic stable angina caused by coronary artery disease. benazepril 102-112 angiotensin I converting enzyme Homo sapiens 61-90 8297690-13 1994 CONCLUSIONS: Benazepril, an angiotensin converting enzyme inhibitor, had a modest anti-ischaemic effect in effort angina, but this effect was not as pronounced as with nifedipine. benazepril 13-23 angiotensin I converting enzyme Homo sapiens 28-57 7867683-1 1994 Pharmacokinetic interaction between benazepril (ACE inhibitor) and amlodipine (calcium channel blocker) was studied in 12 healthy subjects. benazepril 36-46 angiotensin I converting enzyme Homo sapiens 48-51 8221814-1 1993 Ambulatory 24-hour blood pressure monitoring was used to assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE) inhibitor benazepril in combination with the diuretic hydrochlorothiazide (HCTZ) in 17 mildly to moderately hypertensive patients. benazepril 147-157 angiotensin I converting enzyme Homo sapiens 132-135 9114904-2 1993 The pharmacokinetics and pharmacodynamics of single and multiple oral doses of the ACE inhibitor benazepril were investigated in young and elderly normotensive subjects. benazepril 97-107 angiotensin I converting enzyme Homo sapiens 83-86 9114905-10 1993 The changes in kinetics and dynamics observed in the elderly after benazepril are qualitatively similar to those with other ACE inhibitors. benazepril 67-77 angiotensin I converting enzyme Homo sapiens 124-127 8512378-0 1993 Benazepril: a new ACE inhibitor. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 18-21 8512378-1 1993 Benazepril (Lotensin) is an ACE inhibitor that can be safely used in renal and liver disease. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 28-31 8512378-1 1993 Benazepril (Lotensin) is an ACE inhibitor that can be safely used in renal and liver disease. benazepril 12-20 angiotensin I converting enzyme Homo sapiens 28-31 1279278-1 1992 The pharmacokinetics and pharmacodynamics of benazepril, an angiotensin converting enzyme (ACE) inhibitor, were investigated after administration of a single oral 5-mg dose and 7 more doses on consecutive days to hypertensive patients with normal renal function (NRF) and those with impaired renal function (IRF). benazepril 45-55 angiotensin I converting enzyme Homo sapiens 60-89 7679869-3 1993 They were treated with the angiotensin converting enzyme inhibitor benazepril (20 mg) and hydrochlorothiazide (50 mg) for 3 months in a double-blind randomized cross-over study. benazepril 67-77 angiotensin I converting enzyme Homo sapiens 27-56 8359184-1 1993 We have investigated whether the pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride are altered with proteinuria by studying 8 patients with major proteinuria of different causes who were given a single dose of 10 mg p.o. benazepril 92-116 angiotensin I converting enzyme Homo sapiens 78-81 1279278-1 1992 The pharmacokinetics and pharmacodynamics of benazepril, an angiotensin converting enzyme (ACE) inhibitor, were investigated after administration of a single oral 5-mg dose and 7 more doses on consecutive days to hypertensive patients with normal renal function (NRF) and those with impaired renal function (IRF). benazepril 45-55 angiotensin I converting enzyme Homo sapiens 91-94 1632402-9 1992 Benazepril is a well-tolerated angiotensin-converting enzyme inhibitor that provides clinically important improvement in exercise tolerance and in signs and symptoms when given once daily to patients with CHF receiving background therapy with digoxin and a diuretic. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 31-60 1459316-0 1992 Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. benazepril 50-60 angiotensin I converting enzyme Homo sapiens 36-39 1459316-1 1992 To assess the short-term metabolic effects a long-acting non-sulphydryl ACE-inhibitor benazepril on glycaemic control in Type 2 diabetes mellitus and arterial hypertension, 10 hypertensive diabetic patients treated with glibenclamide were studied in a double-blind, crossover fashion over two 10-day periods in which either benazepril (10 mg/day) or placebo was given. benazepril 86-96 angiotensin I converting enzyme Homo sapiens 72-75 1820296-9 1991 The intravenous application of nitroprusside and the ACE-inhibitor benazepril decreased both the systolic stress-time integral and the myocardial oxygen consumption in proportion to each other indicating unchanged economy of myocardial contraction. benazepril 67-77 angiotensin I converting enzyme Homo sapiens 53-56 1316404-4 1992 This deactivation was performed after oral administration of the non-sulphidrylic ACE inhibitor benazepril (10 mg) and placebo according to a double-blind randomized crossover experimental design. benazepril 96-106 angiotensin I converting enzyme Homo sapiens 82-85 1327597-4 1992 Following acute administration of lisinopril, perindopril or benazepril, ACE was markedly inhibited in the lung, kidney and blood vessels but not in the testis. benazepril 61-71 angiotensin I converting enzyme Homo sapiens 73-76 1799889-0 1991 [Effects of benazepril, a new ACE inhibitor, in effort angina pectoris]. benazepril 12-22 angiotensin I converting enzyme Homo sapiens 30-33 1799889-1 1991 The aim of this study was to evaluate the anti-ischemic efficacy of 2 different doses of benazepril (B), a new ACE-inhibitor, 10 and 20 mg, given per os. benazepril 89-99 angiotensin I converting enzyme Homo sapiens 111-114 1720384-2 1991 Benazepril is a nonsulfhydryl ACE inhibitor prodrug, which is converted in vivo to its active form, benazeprilat. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 30-33 1888695-0 1991 Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex. benazepril 56-66 angiotensin I converting enzyme Homo sapiens 15-44 1888695-1 1991 The effects of monotherapy with the angiotensin converting enzyme inhibitor benazepril (10 mg once daily) on cardiovascular baroreceptor reflexes were determined in 10 patients with essential hypertension using a randomized, double-blind, placebo-controlled, cross-over protocol. benazepril 76-86 angiotensin I converting enzyme Homo sapiens 36-65 1893640-5 1991 Side effects believed to be related to the pharmacologic action of ACE inhibitors as a class include symptomatic hypotension, which occurred at a relatively low rate with benazepril, and hyperkalemia and elevation of serum creatinine, which occurred to the same extent with benazepril as has been noted with other ACE inhibitors. benazepril 171-181 angiotensin I converting enzyme Homo sapiens 67-70 1893640-5 1991 Side effects believed to be related to the pharmacologic action of ACE inhibitors as a class include symptomatic hypotension, which occurred at a relatively low rate with benazepril, and hyperkalemia and elevation of serum creatinine, which occurred to the same extent with benazepril as has been noted with other ACE inhibitors. benazepril 274-284 angiotensin I converting enzyme Homo sapiens 67-70 1827977-8 1991 The intravenous application of nitroprusside and the ACE-inhibitor benazepril decreased both the systolic stress-time integral and the myocardial oxygen consumption in proportion to each other, indicating unchanged economy of myocardial contraction. benazepril 67-77 angiotensin I converting enzyme Homo sapiens 53-56 2264573-0 1990 Chronic therapy for congestive heart failure with benazepril HCl, a new angiotensin converting enzyme inhibitor. benazepril 50-64 angiotensin I converting enzyme Homo sapiens 72-101 2264573-1 1990 Benazepril HCl is an orally effective angiotensin converting enzyme (ACE) inhibitor previously shown to have significant acute hemodynamic benefits in patients with congestive heart failure. benazepril 0-14 angiotensin I converting enzyme Homo sapiens 38-67 2264573-1 1990 Benazepril HCl is an orally effective angiotensin converting enzyme (ACE) inhibitor previously shown to have significant acute hemodynamic benefits in patients with congestive heart failure. benazepril 0-14 angiotensin I converting enzyme Homo sapiens 69-72 2258783-4 1990 In the development of the new angiotensin converting enzyme (ACE) inhibitor benazepril, crossover trials were used to obtain useful information. benazepril 76-86 angiotensin I converting enzyme Homo sapiens 30-59 2271751-1 1990 The influence of hepatic disease on the pharmacokinetics of the new ACE inhibitor, benazepril hydrochloride, was evaluated in 12 male patients suffering from liver cirrhosis. benazepril 83-107 angiotensin I converting enzyme Homo sapiens 68-71 2273083-1 1990 Benazepril hydrochloride (CGS 14824A) is an orally active, nonsulfhydryl compound that is transformed in vivo to a long-acting inhibitor of angiotensin-converting enzyme (ACE). benazepril 0-24 angiotensin I converting enzyme Homo sapiens 140-169 2273083-1 1990 Benazepril hydrochloride (CGS 14824A) is an orally active, nonsulfhydryl compound that is transformed in vivo to a long-acting inhibitor of angiotensin-converting enzyme (ACE). benazepril 0-24 angiotensin I converting enzyme Homo sapiens 171-174 1963190-0 1990 Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension. benazepril 77-87 angiotensin I converting enzyme Homo sapiens 36-65 2258783-4 1990 In the development of the new angiotensin converting enzyme (ACE) inhibitor benazepril, crossover trials were used to obtain useful information. benazepril 76-86 angiotensin I converting enzyme Homo sapiens 61-64 2188772-1 1990 This study evaluated the blood pressure effects of administration of once daily oral benazepril hydrochloride, a new angiotensin-converting enzyme (ACE) inhibitor, for mild-to-moderate hypertension. benazepril 85-109 angiotensin I converting enzyme Homo sapiens 117-146 2200924-1 1990 A double-blind, placebo-controlled study was carried out to assess the effects of a three-month treatment with a new ACE inhibitor, Benazepril (BNZ), on systemic and renal hemodynamics, and urine protein excretion, in 20 patients with chronic glomerulonephritis, normal blood pressure (130/83 +/- 16/10 mm Hg), and normal renal function (creatine clearance 106 +/- 25 ml/min). benazepril 132-142 angiotensin I converting enzyme Homo sapiens 117-120 2200924-1 1990 A double-blind, placebo-controlled study was carried out to assess the effects of a three-month treatment with a new ACE inhibitor, Benazepril (BNZ), on systemic and renal hemodynamics, and urine protein excretion, in 20 patients with chronic glomerulonephritis, normal blood pressure (130/83 +/- 16/10 mm Hg), and normal renal function (creatine clearance 106 +/- 25 ml/min). benazepril 144-147 angiotensin I converting enzyme Homo sapiens 117-120 2188772-1 1990 This study evaluated the blood pressure effects of administration of once daily oral benazepril hydrochloride, a new angiotensin-converting enzyme (ACE) inhibitor, for mild-to-moderate hypertension. benazepril 85-109 angiotensin I converting enzyme Homo sapiens 148-151 2687336-1 1989 Renal and hemodynamic effects of diet alone and of single oral doses of the nonsulphydryl angiotensin converting enzyme (ACE) inhibitor, benazepril (10 mg), were investigated in eight healthy volunteers under stable conditions of high salt intake (300 mmol NaCl/day) and low salt intake (10 mmol NaCl/day), in a double blind, placebo controlled study. benazepril 137-147 angiotensin I converting enzyme Homo sapiens 121-124 2344861-0 1990 Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. benazepril 59-83 angiotensin I converting enzyme Homo sapiens 45-48 26428686-3 2015 By decreasing systemic vascular resistance and angiotensin II (AII) production, angiotensin-converting enzyme (ACE) inhibitors such as benazepril improve cardiac hemodynamics and reduce mortality in human and dog CHF patients. benazepril 135-145 angiotensin I converting enzyme Homo sapiens 80-109 2758102-0 1989 Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. benazepril 64-74 angiotensin I converting enzyme Homo sapiens 24-53 2758102-1 1989 The pharmacokinetics of the new angiotensin converting enzyme (ACE) inhibitor benazepril.HCl were evaluated in healthy male volunteers. benazepril 78-88 angiotensin I converting enzyme Homo sapiens 32-61 2758102-1 1989 The pharmacokinetics of the new angiotensin converting enzyme (ACE) inhibitor benazepril.HCl were evaluated in healthy male volunteers. benazepril 78-88 angiotensin I converting enzyme Homo sapiens 63-66 28621557-4 2017 The aim of this study was to examine whether the molecular variations of KLK1 play role in determining the therapeutic response to benazepril, an ACE inhibitor. benazepril 131-141 angiotensin I converting enzyme Homo sapiens 146-149 30594849-0 2019 Multi-spectroscopic approaches and molecular simulation research of the intermolecular interaction between the angiotensin-converting enzyme inhibitor (ACE inhibitor) benazepril and bovine serum albumin (BSA). benazepril 167-177 angiotensin I converting enzyme Homo sapiens 152-155 30594849-1 2019 Benazepril, a common ACE inhibitor, widely used in the treatment of arterial hypertension and congestive heart failure. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 21-24 26759679-3 2015 Review of his antihypertensive medication list revealed that he normally took benazepril, highly suggestive of a diagnosis of angiotensin-converting-enzyme inhibitor-related angioedema (ACEI-RA). benazepril 78-88 angiotensin I converting enzyme Homo sapiens 126-155 26428686-3 2015 By decreasing systemic vascular resistance and angiotensin II (AII) production, angiotensin-converting enzyme (ACE) inhibitors such as benazepril improve cardiac hemodynamics and reduce mortality in human and dog CHF patients. benazepril 135-145 angiotensin I converting enzyme Homo sapiens 111-114 24391962-7 2013 Medication with angiotensin converting enzyme inhibitor benazepril attenuated the blood pressure fluctuation by 2.4/1.3 mmHg each year, though the inverse association of temperature and blood pressure remained. benazepril 56-66 angiotensin I converting enzyme Homo sapiens 16-45 21714597-3 2011 The renoprotective effects of the ACE inhibitor, benazepril, independent of blood pressure control, have been demonstrated, as monotherapy or in combination with amlodipine or hydrochlorothiazide, in large clinical trials: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) and Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension (GUARD) in patients with mild-to-severe chronic kidney disease. benazepril 49-59 angiotensin I converting enzyme Homo sapiens 34-37 22571394-3 2012 OBJECTIVES: The objective of this clinical investigation was to evaluate the antihypertensive effectiveness of monotherapy with the ACE inhibitor benazepril or the CCB amlodipine and their combination in Black and White hypertensive patients in two separate studies. benazepril 146-156 angiotensin I converting enzyme Homo sapiens 132-135 21714597-3 2011 The renoprotective effects of the ACE inhibitor, benazepril, independent of blood pressure control, have been demonstrated, as monotherapy or in combination with amlodipine or hydrochlorothiazide, in large clinical trials: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) and Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension (GUARD) in patients with mild-to-severe chronic kidney disease. benazepril 380-386 angiotensin I converting enzyme Homo sapiens 34-37 20930708-5 2011 A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening. benazepril 120-130 angiotensin I converting enzyme Homo sapiens 73-102 20930708-5 2011 A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening. benazepril 120-130 angiotensin I converting enzyme Homo sapiens 104-107 21108548-1 2010 Benazepril is a nonsulfhydryl ACE inhibitor with favorable pharmacodynamic and pharmacokinetic properties, well-established antihypertensive effects and a good tolerability profile. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 30-33 17395288-0 2007 Benazepril induced isolated visceral angioedema: a rare and under diagnosed adverse effect of angiotensin converting enzyme inhibitors. benazepril 0-10 angiotensin I converting enzyme Homo sapiens 94-123